| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2026-01-19 |
| タイトル |
|
|
タイトル |
Burden of typhoid fever and antimicrobial resistance in India (2023): a modelling study |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Typhoid fever |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Incidence |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Antimicrobial resistance |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Disease burden |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Fluoroquinolone-resistance |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Vaccination |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Typhoid conjugate vaccine |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Prioritisation |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Mogasale, Vijayalaxmi V.
John, Jacob
Sahai, Nikhil
Ray, Arindam
Farooqui, Habib Hasan
Mogasale, Vittal
Dhoubhadel, Bhim Gopal
Edmunds, W. John
Clark, Andrew
Abbas, Kaja
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: India is one of the countries with a high typhoid fever burden. In 2022, the National Technical Advisory Group on Immunisation recommended including the typhoid conjugate vaccine (TCV) in the Universal Immunisation Programme. In this study, we aimed to estimate the 2023 burden of typhoid fever and its antimicrobial resistance (AMR) to inform targeted vaccine introduction strategies. Methods: We used a decision tree model to estimate typhoid cases, hospitalisations, complications, and deaths. Incidence and clinical parameters were derived from a multicentre Indian study, with state-wise AMR prevalence from a systematic review. Two co-primary and four alternative scenarios were presented to validate the robustness of the findings. Findings: We estimated 4.9 million (95% UI: 4.4–5.6) typhoid cases and 7850 (4300–14,900) deaths in India in 2023. Of 730,000 (534,000–970,000) hospitalisations, 600,000 (435,000–799,000; 82%) were attributable to fluoroquinolone-resistant. Under primary scenario A, children <5 years accounted for 321,000 (235,000–427,000; 44.0%) hospitalisations and 2600 (1300–4800; 34.0%) deaths. Under primary scenario B, 5–9 years of age accounted for 265,000 (135,000–278,000; 36.0%) hospitalisations and 2900 (1500–5300; 36.0%) deaths. Delhi, Maharashtra, and Karnataka together accounted for 29% of the national burden and had the highest rates of fluoroquinolone-resistant cases and deaths among the ten highest-burden states. Deaths linked to fluoroquinolone-resistance, multidrug resistance, third-generation cephalosporins, and azithromycin resistance were 4700 (1800–10,200), 122 (45–294), 183 (69–431), and 183 (68–432), respectively. Interpretation: Fluoroquinolone-resistance drives a large share of typhoid-related hospitalisations and deaths, especially in children under five and in high-burden states of India. Targeted TCV introduction, with broader age coverage among children, would maximise impact. Funding: WISE programme; Vaccine Impact Modelling Consortium; Japan Agency for Medical Research and Development. |
|
言語 |
en |
| 書誌情報 |
en : The Lancet Regional Health - Southeast Asia
巻 44,
p. art. no. 100714,
発行日 2026-01-07
|
| 出版者 |
|
|
出版者 |
Elsevier Ltd |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
27723682 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1016/j.lansea.2025.100714 |
| 権利 |
|
|
権利情報 |
© 2026 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
The Lancet Regional Health - Southeast Asia, 44, art. no. 100714; 2026 |
|
言語 |
en |
TLRHSA44_100714.pdf (1.9 MB)
